Skip to main content

Select Drug Profiles

Multiple Myeloma, Oncology
Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma
Chase Doyle
Chase Doyle
Read More
Daratumumab Enhances Remissions When Added to Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals
Dual-Specific CAR T-Cell Therapy Targets CD19 and CD22 in Patients with Acute Lymphoblastic Leukemia
Chase Doyle
Chase Doyle
Read More
Rapid Progress in Aggressive Hematologic Malignancies Highlighted at ASH 2018
Wayne Kuznar
Wayne Kuznar
Read More
Leukemia, Oncology
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals
AMG 420, a Novel BiTE, Shows Impressive Responses in Heavily Treated Patients with Multiple Myeloma
Wayne Kuznar
Wayne Kuznar
Read More
Leukemia, Oncology
First-Line Enasidenib Achieves Complete Remission in Older Patients with Acute Myeloid Leukemia and IDH2 Mutation
Charles Bankhead
Charles Bankhead
Read More
Leukemia, Oncology
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
Phoebe Starr
Read More
Lymphoma
Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma
Wayne Kuznar
Phoebe Starr
Read More
Immunotherapy, Oncology
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
Phoebe Starr
Phoebe Starr
Read More
Page 58 of 244
Results 571 - 580 of 2434